JLPC(SH:600513)2017-10-27 16:00Financial Performance - Net profit attributable to shareholders rose by 9.82% to CNY 50,196,829.22 for the first nine months of the year[6] - Operating revenue for the first nine months increased by 1.86% to CNY 478,478,017.19 compared to the same period last year[6] - The net profit for the reporting period decreased by 49.29% compared to the same period last year, amounting to ¥25,096,495.96[13] - Investment income increased by 114.16%, reaching ¥2,514,025.74 due to the sale of equity in associated companies[13] - Total operating revenue for Q3 2017 was CNY 182,797,304.53, an increase of 15.06% compared to CNY 158,910,596.55 in Q3 2016[26] - Net profit for Q3 2017 was CNY 14,745,900.92, a decrease of 9.66% from CNY 16,328,606.27 in Q3 2016[27] - The company reported a total profit of CNY 15,415,250.10 for Q3 2017, compared to CNY 14,345,817.74 in Q3 2016, marking an increase of approximately 7.4%[30] Cash Flow - The net cash flow from operating activities decreased by 49.29% to CNY 25,096,495.96 year-to-date[6] - Cash flow from operating activities decreased by 49.29%, amounting to ¥25,096,495.96, indicating a decline in cash collection[13] - Cash flow from investing activities showed a significant increase of 116.95%, reaching ¥7,015,071.39 due to the sale of equity in associated companies[13] - Net cash flow from operating activities for Q3 2017 was CNY 15,250,140.99, a decrease of 58.8% compared to CNY 36,963,058.85 in Q3 2016[35] - Cash outflow from investing activities totaled CNY 36,070,625.55 in Q3 2017, compared to CNY 29,819,440.33 in Q3 2016, indicating an increase of 20.5%[35] - Net cash flow from investing activities for Q3 2017 was CNY 7,729,374.45, recovering from a negative cash flow of CNY 29,819,440.33 in the same quarter last year[35] - Net cash flow from financing activities showed a negative figure of CNY -19,871,238.43 in Q3 2017, worsening from CNY -11,154,828.17 in Q3 2016[35] Assets and Liabilities - Total assets increased by 1.18% to CNY 1,078,909,618.83 compared to the end of the previous year[6] - Total liabilities decreased from ¥239,031,207.78 to ¥221,117,508.07, reflecting a reduction in short-term borrowings[19] - The company's equity attributable to shareholders increased to ¥857,744,846.52 from ¥826,704,917.13, indicating growth in retained earnings[19] - Total assets as of September 30, 2017, were ¥1,078,909,618.83, an increase from ¥1,066,283,951.98 at the beginning of the year[19] - Total liabilities increased to CNY 158,776,646.64 in Q3 2017, up from CNY 136,287,686.28 in Q3 2016, representing a rise of 16.54%[23] - The company's total equity reached CNY 806,397,973.36, an increase from CNY 787,159,383.73 in the previous year, indicating a growth of 2.93%[23] Shareholder Information - The number of shareholders reached 22,351 by the end of the reporting period[10] - The company’s major shareholder, Jiangsu Lianhuan Pharmaceutical Group Co., Ltd., holds 37.09% of the shares[10] Inventory and Expenses - Inventory increased by 32.16% to CNY 85,861,157.33 due to sales growth and increased raw material[12] - Total operating costs for Q3 2017 were CNY 165,349,411.61, up 17.93% from CNY 140,175,048.18 in Q3 2016[26] - Sales expenses for Q3 2017 were CNY 80,784,466.57, a significant increase of 46.94% compared to CNY 54,907,895.90 in Q3 2016[26] - Sales expenses for Q3 2017 were CNY 43,506,347.83, a decrease of 3.7% compared to CNY 45,182,724.79 in Q3 2016[29] Future Plans - The company has plans for market expansion and new product development, although specific details were not disclosed in the report[27]